Point72 Asset Management, L.P. - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 131 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.40 and the average weighting 0.0%.

Quarter-by-quarter ownership
Point72 Asset Management, L.P. ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2019$14,079,000
-61.1%
2,785,100
-52.5%
0.09%
-54.5%
Q2 2019$36,148,000
+34.3%
5,858,749
+1.0%
0.19%
+54.9%
Q1 2019$26,912,000
+34.2%
5,800,000
+21.5%
0.12%
+24.5%
Q4 2018$20,055,0004,775,0000.10%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q4 2019
NameSharesValueWeighting ↓
Phocas Financial Corp. 1,033,328$6,376,0000.68%
ARDSLEY ADVISORY PARTNERS LP 650,000$4,011,0000.63%
Worth Venture Partners, LLC 138,357$853,0000.47%
RICE HALL JAMES & ASSOCIATES, LLC 2,242,503$13,836,0000.46%
HIGHLAND CAPITAL MANAGEMENT LP 716,880$4,423,0000.26%
FARALLON CAPITAL MANAGEMENT LLC 5,543,386$34,203,0000.22%
Point72 Asset Management, L.P. 5,858,749$36,148,0000.19%
PINNACLE ASSOCIATES LTD 1,298,723$8,013,0000.19%
Fosun International Ltd 472,580$2,750,0000.18%
J. Goldman & Co LP 400,000$2,468,0000.17%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders